Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs July 27, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia July 23, 2021 • 4:40 PM EDT
Commercial Scale Vaccine Manufacturing Facility Advances In The Bitterfoot June 24, 2021 • 1:30 PM EDT
Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC) June 21, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference June 16, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting June 3, 2021 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Presentation of Two Posters at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting May 26, 2021 • 7:00 AM EDT
